Brett Esq - Theravance Biopharma General VP
| TBPH Stock | USD 9.61 0.36 3.61% |
VP
Brett Esq is General VP of Theravance Biopharma
| Age | 50 |
| Address | 901 Gateway Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 808 6000 |
| Web | https://www.theravance.com |
Theravance Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.0641) % which means that it has lost $0.0641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2288) %, meaning that it created substantial loss on money invested by shareholders. Theravance Biopharma's management efficiency ratios could be used to measure how well Theravance Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.15. The Theravance Biopharma's current Return On Capital Employed is estimated to increase to -0.14. As of now, Theravance Biopharma's Non Current Assets Total are increasing as compared to previous years. The Theravance Biopharma's current Non Currrent Assets Other is estimated to increase to about 213.3 M, while Other Current Assets are projected to decrease to under 11.4 M.Similar Executives
| Found 3 records | VP Age | ||
| Moses CPA | Nuvation Bio | 45 | |
| Stephen Dang | Nuvation Bio | N/A | |
| JD Rowland | CytomX Therapeutics | 67 | |
Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0641 |
Theravance Biopharma Leadership Team
Elected by the shareholders, the Theravance Biopharma's board of directors comprises two types of representatives: Theravance Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theravance. The board's role is to monitor Theravance Biopharma's management team and ensure that shareholders' interests are well served. Theravance Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theravance Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aziz CFA, Senior CFO | ||
| Rhonda Farnum, Chief Affairs | ||
| Andrew MBA, VP CFO | ||
| Stacy Pryce, Senior Officer | ||
| Stuart Knight, Senior Officer | ||
| Gail Cohen, Vice Relations | ||
| Rick MBA, Chairman CEO | ||
| Brett Esq, General VP | ||
| Aine Miller, VP Dev | ||
| Richard Graham, Strategic Advisor |
Theravance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theravance Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0641 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (0.55) % | ||||
| Current Valuation | 426.18 M | ||||
| Shares Outstanding | 49.17 M | ||||
| Shares Owned By Insiders | 5.92 % | ||||
| Shares Owned By Institutions | 96.75 % | ||||
| Number Of Shares Shorted | 4.92 M | ||||
| Price To Earning | (6.20) X |
Currently Active Assets on Macroaxis
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.03) | Revenue Per Share 1.293 | Quarterly Revenue Growth 0.075 | Return On Assets (0.06) | Return On Equity (0.23) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.